Globenewswire·2025-11-25 13:00Core Insights - Prime Medicine, Inc. is participating in the 8th Annual Evercore Healthcare Conference on December 2, 2025, with CEO Allan Reine as a speaker [1] - The company focuses on developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform [3] Company Overview - Prime Medicine is a biotechnology company dedicated to gene editing therapies, utilizing a precise and efficient technology that minimizes unwanted DNA modifications [3] - The Prime Editing platform has the potential to repair various genetic mutations across multiple tissues, organs, and cell types, unlocking opportunities for thousands of potential indications [3] Therapeutic Programs - The company is advancing a diversified portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology [4] - Each program targets diseases with well-understood biology and a clear clinical development path, aiming to expand into additional opportunities over time [4] - Prime Medicine plans to leverage the versatility of its Prime Editing platform to address a wide range of genetic, immunological, and infectious diseases, impacting millions of people [4]